Antengene Corporation is a clinical-stage biopharmaceutical company founded by Dr. Jay Mei focusing on introducing cutting-edge treatments, ranging from mid-to-late stage development pipelines to mature brands, to China and other Asian markets. Antengene establishes long-term cooperation with Celgene by IP authorization and equity cooperation. Antengene has in-licensed TORC1/TORC2 inhibitor ATG-008 (CC-223). ATG-008 is an innovative drug targeting HCC in clincial trial stage in US and Europe.